Evidence map›Paper›PMID 37072663›Full record

ArticleThe patient2023

Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.

Edward J D Webb, David Meads, Ieva Eskytė, Helen L Ford, Hilary L Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue H Pavitt and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in The patient, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Edward J D WebbLeeds Institute of Health Sciences, University of Leeds, Leeds, UK. e.j.d.webb@leeds.ac.uk.ORCID 0000-0001-7918-839X
David MeadsLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Ieva EskytėSchool of Law, University of Leeds, Leeds, UK.
Helen L FordLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Hilary L BekkerLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Jeremy ChatawayQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK.
George PepperShift.ms, Leeds, UK.
Joachim MartiCentre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Yasmina OkanCentre for Decision Research, Leeds University Business School, University of Leeds, Leeds, UK.
Sue H PavittDental Translational and Clinical Research Unit, School of Dentistry, University of Leeds, Leeds, UK.
Klaus SchmiererBlizard Institute (Neuroscience) Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Ana ManzanoSchool of Sociology and Social Policy, University of Leeds, Leeds, UK.
University of Leeds · GBQueen Mary University of London · GBCentre universitaire de médecine générale et santé publique, Lausanne · CHLeeds Teaching Hospitals NHS Trust · GBShift (United Kingdom) · GB

Funding

Cancer Research UK C57775/A22182Department of HealthMultiple Sclerosis Society 30
6 · The paper itself

Abstract

backgroundPeople with relapsing-remitting multiple sclerosis can benefit from disease-modifying treatments (DMTs). Several DMTs are available that vary in their efficacy, side-effect profile and mode of administration.

objectiveWe aimed to measure the preferences of people with relapsing-remitting multiple sclerosis for DMTs using a discrete choice experiment and to assess which stated preference attributes correlate with the attributes of the DMTs they take in the real world.

methodsDiscrete choice experiment attributes were developed from literature reviews, interviews and focus groups. In a discrete choice experiment, participants were shown two hypothetical DMTs, then chose whether they preferred one of the DMTs or no treatment. A mixed logit model was estimated from responses and individual-level estimates of participants' preferences conditional on their discrete choice experiment choices calculated. Logit models were estimated with stated preferences predicting current real-world on-treatment status, DMT mode of administration and current DMT.

resultsA stated intrinsic preference for taking a DMT was correlated with currently taking a DMT, and stated preferences for mode of administration were correlated with the modes of administration of the DMTs participants were currently taking. Stated preferences for treatment effectiveness and adverse effects were not correlated with real-world behaviour.

conclusionsThere was variation in which discrete choice experiment attributes correlated with participants' real-world DMT choices. This may indicate patient preferences for treatment efficacy/risk are not adequately taken account of in prescribing. Treatment guidelines must ensure they take into consideration patients' preferences and improve communication around treatment efficacy/risk.

Indexed as

Drug-Related Side Effects and Adverse ReactionsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingDecision MakingHumansTreatment Outcome

Identifiers

PMID37072663
OpenAlexW4366251539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.